ArticleInternational journal of clinical oncology2026
Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitor (ICI)-based combination therapies have become the standard first-line treatment for metastatic renal cell carcinoma (mRCC). This study evaluated the prognostic significance of early tumor shrinkage in patients with mRCC treated with first-line ICI-based combination therapies.
methodsWe retrospectively reviewed 169 mRCC patients who received nivolumab plus ipilimumab, pembrolizumab (or avelumab) plus axitinib, pembrolizumab plus lenvatinib, or nivolumab plus cabozantinib at Kobe University Hospital and its affiliated institutions. Patients were stratified into four groups according to early tumor shrinkage at the first imaging assessment after therapy initiation. The association between early tumor shrinkage and the overall survival (OS) was analyzed.
resultsThe median early tumor shrinkage rate was 17.8%. Twenty-one patients (12.4%) had 50-100% shrinkage, 31 (18.3%) had 30-<50% shrinkage, 81 (47.9%) had 0-<30% shrinkage, and 36 (21.3%) showed progression. The median OS was 42.4 months. The corresponding median OS by shrinkage category above was not reached (NR), NR, 34.7 months, and 30.8 months, respectively (p = 0.023), with 2-year OS rates of 86.7%, 75.1%, 66.1%, and 60.5%, respectively. A univariate analysis identified a prior nephrectomy, International mRCC Database Consortium risk group, bone or liver metastasis, C-reactive protein level, histological subtype, and early tumor shrinkage as predictors of the OS. In the multivariate analysis, prior nephrectomy, bone or liver metastasis, histological subtype, and early tumor shrinkage remained independent.
conclusionEarly tumor shrinkage was independently associated with the OS, suggesting its potential as a prognostic indicator in patients with mRCC treated with first-line ICI-based combination therapy.
Indexed as
Identifiers
42156608What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.